

REMARKS:

Claims 1-11 have been allowed and claims 12-15 stand rejected.

By the above amendments, claims 10-13 have been cancelled and new method claims 14, 15 and 16 have been added. Support for new claims 14-16 is found in the specification at pages 62 and 63, and in the Biological Assays beginning at page 54, line 10.


Following entry of these amendments, claims 1-9 and 14-16 remain pending in this application.

Claim Rejections

Method claims 12-15 have been rejected for various grounds as to form, the Examiner suggesting that they be put in a proper method of treatment form. These grounds for rejection have all been obviated by the cancellation of claims 12-15 above, and with their replacement by new method of treatment claims 16-18, which are in a proper method of treatment form. Specification support for these new claims is noted above. No new matter has been added, and entry and allowance of these claims is believed to be in order and is respectfully requested.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Donald J. Bud
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: July 25, 2006
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By: